Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data
Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)
Related NVS
Update on BioLineRx's BL-8040 - Analyst Blog
Balanced Risk-Reward for The Cooper Companies - Analyst Blog
Hang Out on the Sidelines (Fox Business)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Most Popular

Related Articles (TEVA + NVS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free